Patents Assigned to Janssen Vaccines & Prevention B.V.
-
Patent number: 11459583Abstract: Provided herein are chimeric adenoviral vectors. The provided chimeric adenoviral vectors can be used to induce a protective immune response in a subject.Type: GrantFiled: October 30, 2018Date of Patent: October 4, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Taco Gilles Uil, Soumitra Roy, Jort Vellinga, Selina Khan, Jerome H. Hv. Custers
-
Patent number: 11447526Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.Type: GrantFiled: January 22, 2019Date of Patent: September 20, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Ferdinand Jacobus Milder, Tina Ritschel, Boerries Brandenburg, Mandy Antonia Catharina Jongeneelen, Daphné Truan, Johannes Petrus Maria Langedijk
-
Patent number: 11365222Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.Type: GrantFiled: August 13, 2020Date of Patent: June 21, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes P. M. Langedijk
-
Patent number: 11338031Abstract: The present invention relates to novel nucleic acid molecules encoding a pre-fusion RSV F protein or immunologically active part thereof, wherein the pre-fusion RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2. The invention further relates to the use of the nucleic acid molecules, or vectors comprising said nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV).Type: GrantFiled: June 24, 2020Date of Patent: May 24, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Johannes Petrus Maria Langedijk, Janneke M. Verhagen
-
Patent number: 11322228Abstract: A method of designing a D-polypeptide that binds with an L-target protein can include: identifying a polypeptide target having L-chirality; determining hotspot amino acids of a polypeptide ligand having L-chirality that have binding interactions with the L-target protein; determining transformations of side chains of the hotspot amino acids that retain the binding interactions with the target; generating inversed hotspot amino acids with chirality opposite to the one of the target; identifying a polypeptide having inverse chirality from the target protein, on which a combination of inversed hotspot amino-acid can be grafted without significantly changing their interactions with the target. The designed ligands can be processed and converted to D-ligands that bind with the L-target protein.Type: GrantFiled: October 27, 2016Date of Patent: May 3, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Jaroslaw Juraszek, Davide Branduardi, Ronald Vogels, Robert Heinz Edward Friesen
-
Patent number: 11306292Abstract: Described are compositions comprising enveloped viruses that are not MVA, a sulfate salt at a concentration of about 5 mM to about 300 mM and a buffer, and the composition has a pH of about 6.0 to about 8.5. It also discloses methods for stabilizing an enveloped virus composition by preparing said viral formulation.Type: GrantFiled: May 15, 2018Date of Patent: April 19, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Ahmad Shakeb Sediq, Wouter Frank Tonnis, Martinus Anne Hobbe Capelle
-
Patent number: 11274147Abstract: The invention relates to binding molecules and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using the binding molecules or antigen-binding fragments.Type: GrantFiled: January 31, 2019Date of Patent: March 15, 2022Assignee: JANSSEN VACCINES & PREVENTION B.V.Inventors: Constantin Adrian Apetri, Jaroslaw Juraszek, Roosmarijn Janson, Harmke Cornelia Verveen, Bunga Berdien Siregar
-
Patent number: 11249093Abstract: The present invention provides a method for the in vitro formation and/or detection of paired helical filaments (PHF) of Tau protein, comprising incubating a mixture comprising a Tau protein preparation and a polyanionic co-factor for a pre-determined period of time under conditions that promote the formation of PHFs.Type: GrantFiled: March 27, 2018Date of Patent: February 15, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Rosa Crespo Rodriguez, Constantin Adrian Apetri
-
Patent number: 11235051Abstract: Compositions and methods are described for inducing an immune response against an immunogen in humans. The induced immune response is obtained by administering a heterologous prime-boost combination of an in vitro transcribed (IVT) self-replicating RNA (repRNA) and an adenovirus vector. The compositions and methods can be used to provide a protective immunity against a disease, such as a viral infection or a cancer, in humans.Type: GrantFiled: July 27, 2018Date of Patent: February 1, 2022Assignees: Janssen Vaccines & Prevention B.V., Massachusetts Institute of TechnologyInventors: Ronald Vogels, Marijn Van Der Neut Kolfschoten, Darrell J. Irvine, Ron Weiss, Ely Blanton Porter, Mariane Bandeira Melo, Tasuku Kitada
-
Patent number: 11236361Abstract: Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.Type: GrantFiled: October 30, 2018Date of Patent: February 1, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Taco Gilles Uil, Soumitra Roy, Selina Khan, Jerôme H. H. V. Custers
-
Patent number: 11229694Abstract: Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.Type: GrantFiled: October 1, 2019Date of Patent: January 25, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Johannes Petrus Maria Langedijk, Dirk André Emmy Roymans
-
Patent number: 11229695Abstract: Methods of inducing a safe immune response against respiratory syncytial virus (RSV) in a human subject in need thereof, including administering to the subject a composition including recombinant adenovirus including a nucleic acid encoding an RSV Fusion (F) protein including the amino acid sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier, in a total dose of from about 1×1010 to about 2×1011 viral particles (vp), are described.Type: GrantFiled: September 13, 2018Date of Patent: January 25, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Myra Noorely Widjojoatmodjo, Olivier Godeaux, Kristi Lynn Williams, Benoit Christophe Stephan Callendret, Jerald C. Sadoff
-
Patent number: 11229693Abstract: Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided. Also provided are vaccine combinations containing the disclosed poxvirus vectors, adenovirus vectors encoding one or more HIV antigens, and one or more isolated HIV antigenic polypeptides, and methods of using the vaccine combinations to provide improved immunity against HIV.Type: GrantFiled: June 14, 2018Date of Patent: January 25, 2022Assignees: Janssen Vaccines & Prevention B.V., Bavarian Nordic A/SInventors: Frank Wegmann, Johannes Petrus Maria Langedijk, Jerôme Hubertina Henricus Victor Custers, Viki Bockstal, Markus Kalla
-
Patent number: 11229692Abstract: Compositions, vaccines and methods using adenovirus vectors for inducing protective immunity against a respiratory syncytial virus (RSV) infection are described.Type: GrantFiled: May 15, 2018Date of Patent: January 25, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Olivier Godeaux, Jerald C. Sadoff, Macaya Julie Douoguih
-
Patent number: 11207400Abstract: Compositions, vaccines and methods for inducing an immunity, including a protective immunity, against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more adenovirus 26 vectors using for priming immunization and an isolated HIV antigenic polypeptide in combination with one or more MVA vectors for boosting immunization induced strong protective immunity against infections by one or multiple clades of HIV.Type: GrantFiled: October 4, 2019Date of Patent: December 28, 2021Assignees: Janssen Vaccines & Prevention B.V., Beth Israel Deaconess Medical Center, Inc.Inventors: Dan Barouch, Johanna Schuitemaker, Maria Grazia Pau, Danielle Van Manen, Frank Tomaka, Jennifer Anne Hendriks
-
Patent number: 11173204Abstract: Compositions and methods are described for generating an improved effective immune response against an immunogen in humans. The enhanced immune response, is obtained by using an MVA vector as a prime, an adenovirus vector as a first boost, and an adenovirus vector as a second boost. The compositions and methods can be used to provide a protective immunity against a disease, such as an infection of one or more subtypes of Ebola and Marburg filoviruses, in humans.Type: GrantFiled: April 6, 2018Date of Patent: November 16, 2021Assignees: Janssen Vaccines & Prevention B.V., Bavarian Nordic A/SInventors: Benoit Christophe Stephan Callendret, Kerstin Luhn-Wegmann
-
Patent number: 11173201Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.Type: GrantFiled: October 17, 2019Date of Patent: November 16, 2021Assignees: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
-
Patent number: 11155583Abstract: Stable pre-fusion respiratory syncitial virus (RSV) F proteins (or fragment thereof) are described. Compositions containing the proteins and uses of the compositions for the prevention and/or treatment of RSV infection are also described.Type: GrantFiled: April 4, 2017Date of Patent: October 26, 2021Assignee: Janssen Vaccines & Prevention B.V.Inventors: Anders Krarup, Johannes Petrus Maria Langedijk
-
Patent number: 11142551Abstract: Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.Type: GrantFiled: October 30, 2018Date of Patent: October 12, 2021Assignee: Janssen Vaccines & Prevention B.V.Inventors: Taco Gilles Uil, Soumitra Roy, Selina Khan, Jerôme H. H. V. Custers
-
Patent number: 11040963Abstract: The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity while having low cytotoxity. Furthermore, the present invention relates to pharmaceutical compositions comprising said piperazine derivatives, methods of preparing said piperazine derivatives, as well as said piperazine derivatives for use in medical prevention or treatment, especially for preventing or treating influenza.Type: GrantFiled: February 1, 2018Date of Patent: June 22, 2021Assignee: JANSSEN VACCINES & PREVENTION B.V.Inventors: Maria Van Dongen, Jaroslaw Juraszek, Griet Wim Bert Schepens, Charles Edward Lawson, Brian Shook, Maria Tim Hugo Jonckers, Abdellah Tahri, Bernard Pierre Jean-Marie Raboisson, Nestor CHristophe Francis Robert Buyck